Trial Profile
Sub-Clinical Atrial Fibrillation Biomarker (SCAF-b): A Sub-study of Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Aspirin
- Indications Thromboembolism
- Focus Biomarker; Pharmacodynamics
- Acronyms SCAF-b
- 01 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 01 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.